Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Clinical Trial ID NCT01431547

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Monoclonal antibodies in cancer therapy.	Oncoimmunology	2013	1.41
2	New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.	Clin Cancer Res	2013	1.02
3	Targeted therapies for bone sarcomas.	Bonekey Rep	2013	0.85
4	Bone sarcomas: from biology to targeted therapies.	Sarcoma	2012	0.82
5	Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.	Front Oncol	2013	0.79
6	Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.	Oncol Rev	2013	0.79
7	Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.	Nat Rev Clin Oncol	2016	0.78
8	Medulloblastoma development: tumor biology informs treatment decisions.	CNS Oncol	2015	0.78
9	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.	Oncoimmunology	2015	0.77
10	Advances in paediatric cancer treatment.	Transl Pediatr	2014	0.76